Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

RSS icon

Some weight loss patients are overdosing on semaglutide, FDA warns

Compounded semaglutide injectable products are at the heart of these concerns. While the FDA says compounded drugs “can serve an important medical need for patients,” the agency does not approve these new formulations, increasing the risk of complications. 

cardiologist doctor physician patient black diverse hypertension

The 25 top US hospitals for diabetes care

U.S. News and World Report reviewed 660 hospitals, ranking them based on data related to treating diabetes and endocrinology. 

CDC-funded program improved cardiovascular health of low-income Nebraska women

The WISEWOMAN program proved to be a useful intervention to screen low-income, uninsured women and offer them risk reduction counseling to improve blood pressure, diet and physical activity.

Dexcom, a global healthcare technology company based out of San Diego, has received U.S. Food and Drug Administration (FDA) clearance for Stelo, a wearable glucose biosensor that can be obtained without a prescription.

FDA clears first over-the-counter wearable device for continuous glucose monitoring

The newly cleared device is worn on the back of the arm and sends data directly to the user's smartphone. 

doctor with overweight patient who may be treated with TAVR or surgery

Are GLP-1 agonists safe? FDA finds no evidence popular weight loss medications cause suicidal thoughts or actions

The popular drugs, originally developed to treat diabetes, are being used more and more in the United States to help obese and overweight patients lose weight.  

business launch

‘A true breakthrough’: The eye-opening potential of GLP-1 agonists to treat heart, kidney disease in addition to obesity

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

healthcare money economics dollar stethoscope acquire merger

Roche spends $2.7B to acquire biotech company with multiple obesity, diabetes drugs in development

Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.

CVD deaths have increased dramatically, undoing years of progress

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

Displaying 17 - 24 of 58

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.